India’s pharmaceutical and healthcare sector recorded a total of 78 deals valued at approximately $1.9 billion in the first quarter of 2026, according to a recent industry report. While the number of transactions remained stable, overall deal value saw a moderation due to the absence of large-scale transactions, indicating a more cautious investment environment.
The report highlighted that mergers and acquisitions accounted for 30 deals worth about $915 million during the quarter. Although deal volumes remained consistent, the overall value declined by nearly 40% compared to the previous quarter. This trend was largely driven by smaller transaction sizes and a shift toward more selective investment strategies.
Industry experts noted that private equity activity remained active in terms of participation but continued to focus on smaller investment sizes. Investors are increasingly prioritizing scalable and capability-driven businesses, particularly in segments such as digital health, specialised care, and consumer-focused healthcare services. This reflects a broader strategic shift toward long-term value creation and global competitiveness within the sector.
Domestic transactions continued to dominate the M&A landscape in terms of volume. Most deals were relatively small, typically under $50 million, especially in hospital networks, pharmaceuticals, and biotechnology. This pattern suggests ongoing consolidation within mid-market healthcare providers, particularly through regional hospital acquisitions and smaller pharma deals.
Private equity and venture capital investments showed strong momentum, with 45 deals collectively valued at $456 million. This marked the highest deal volume since Q2 2022 and represented an increase of around 22% compared to the previous quarter. A significant share of investments flowed into health technology, wellness platforms, AI-enabled diagnostics, preventive healthcare solutions, and digital care services, highlighting strong investor interest in technology-driven healthcare models.
Early-stage funding remained dominant, with pre-seed to Series A rounds accounting for nearly 69% of total deal volume. Additionally, around 95% of all transactions were valued below $50 million, reinforcing the trend toward early-stage and growth-focused investments.
Public market activity remained limited during the quarter. Only one initial public offering was recorded, raising approximately $18 million, while qualified institutional placement activity saw two issuances totaling around $500 million.
Overall, the data reflects a healthcare investment landscape that is becoming more selective, with strong emphasis on digital innovation, mid-market consolidation, and long-term strategic positioning in India’s evolving pharma and healthcare ecosystem.
